Boardroom Alpha
Boardroom Alpha
CVS · Additional Proxy Materials (DEFA14A) · Filed April 3, 2026

Cvs Health Corp — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 3, 2026
Ticker
CVS
Accession
0001308179-26-000202
Boardroom Alpha · Filing insights

CVS Health Corporation's board recommends voting For all listed directors and key 2026 proposals.

About Cvs Health Corp
Market cap
$114.2B
1Y TSR
+43.6%
3Y TSR
+13.7%
Board grade
C+
Sector
Healthcare
CEO
J David Joyner
Last annual meeting: May 14, 2026 · View full Cvs Health Corp profile →
CVS HEALTH CORPORATION DEFA 14A

UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, DC 20549

 

SCHEDULE 14A

 

PROXY STATEMENT PURSUANT TO SECTION 14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No.     )

 

  Filed by the Registrant   Filed by a Party other than the Registrant

 

Check the appropriate box:
Preliminary Proxy Statement
Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(E)(2))
Definitive Proxy Statement
Definitive Additional Materials
Soliciting Material under ss.240.14a-12

 

CVS Health Corporation

 

 

(Name of Registrant as Specified in Its Charter)

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check all boxes that apply):
No fee required.
Fee paid previously with preliminary materials.
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
 

 

      Your Vote Counts!  
      CVS HEALTH CORPORATION  
 

 

CVS HEALTH CORPORATION
C/O EQUINITI SHAREOWNER SERVICES
P.O. BOX 64945
ST. PAUL, MN 55164-0945

 

2026 Annual Meeting

May 14, 2026 at 8:00 A.M., ET
www.virtualshareholdermeeting.com/CVS2026

Vote by May 13, 2026 at 11:59 P.M., ET

 
       
       
       
         
         
         
         
         
         
  V88956-P47890

     
       

 

You invested in CVS HEALTH CORPORATION and it’s time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the Annual Meeting of Stockholders to be held on May 14, 2026.

 

Get informed before you vote

View the Notice of 2026 Annual Meeting of Stockholders and Proxy Statement and the 2025 Annual Report to Stockholders online OR you can receive a free paper or email copy of the material(s) by requesting prior to April 30, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

 

     
For complete information and to vote, visit www.ProxyVote.com
Control #
     

 

Smartphone users

 

Point your camera here and
vote without entering a
control number

   

We urge you to vote in advance, but you may also vote virtually at the Annual Meeting*

 

May 14, 2026
8:00 A.M., ET

 

 

Virtually at:
www.virtualshareholdermeeting.com/CVS2026

       

 

* Please check the meeting materials for any special requirements for meeting attendance.
 
Vote at www.ProxyVote.com  

 

THIS IS NOT A VOTABLE BALLOT

 

 

This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.

       

 

Voting Items Board
Recommends
1. Election of Directors  
  Nominees:              
1a. Fernando Aguirre  For
1b. Jeffrey R. Balser, M.D., Ph.D.  For
1c. C. David Brown II  For
1d. Alecia A. DeCoudreaux  For
1e. Anne M. Finucane  For
1f. John E. Gallina  For
1g. J. David Joyner  For
1h. J. Scott Kirby  For
1i. Michael F. Mahoney  For
1j. Leslie V. Norwalk  For
1k. Larry M. Robbins  For
1l. Guy P. Sansone  For
1m. Douglas H. Shulman  For
2. Ratification of the Appointment of Our Independent Registered Public Accounting Firm for 2026.  For
3.

Say on Pay, a Proposal to Approve, on an Advisory Basis, the Company’s Executive Compensation.

 For
4. Proposal to Approve the Company’s 2026 Incentive Compensation Plan.  For
5. Stockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent.  Against
NOTE: In their discretion, the proxies may vote on such other business as may properly come before the meeting or any adjournment thereof.  
   
   
   
   
Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.
 
V88957-P47890
 
From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Cvs Health Corp (CVS)

Reference

Frequently asked questions

When did Cvs Health Corp file this DEFA14A?
Cvs Health Corp (CVS) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 3, 2026. The accession number assigned by EDGAR is 0001308179-26-000202.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
CVS Health Corporation's board recommends voting For all listed directors and key 2026 proposals. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Cvs Health Corp's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Cvs Health Corp has filed under CIK 64803, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer